Magnitude and nature of noncompliance with treatment using isosorbide dinitrate in patients with ischemic heart disease

Journal of Clinical Pharmacology

Volumn 36, Issue 7, 1996, Pages 587-594

  Straka, Robert J ^a,b   Fish, Jeffrey T ^a,b   Benson, Steven R ^a,b   Suh, J Thomas ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b REGIONS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOSORBIDE DINITRATE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT MONITORING;

EID: 0029783327     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04222.x     Document Type: Article

References (16)

1. National Cholesterol Education Program (NCEP): second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Circulation 1994;89:1333-1445.
2. Abrams J: Interval therapy to avoid nitrate tolerance: paradise regained? Am J Cardiol 1989;64:931-934.
3. Amsterdam E: Rationale for intermittent nitrate therapy. Am J Cardiol 1992;70:55G-60G.
4. Elkayam U: Tolerance to organic nitrates: evidence, mechanisms, clinical relevance, and strategies for prevention. Ann Intern Med 1991;114:667-677.
5. Gorlin R, Metcalf HL: Optimizing antianginal therapy: consensus guidelines. Am J Cardiol 1992;70:72Q-76Q.
6. Mangione NJ, Glasser SP: Phenomenon of nitrate tolerance. Am Heart J 1994;128:137-146.
7. Parker JO, Farrell B, Lahey KA, Moe G: Effect of intervals between doses on the development of tolerance to isosorbide dinitrate. N Eng J Med 1987;316:1440-1444.
8. Zeller F: Tolerance to organic nitrates in ischemic heart disease. Drug Intell Clin Pharm 1987;21:857-864.
9. Seabra-Gomes R, Aleixo AM, Adao M, Machado FP, Mendos M, Bruges G, Palos JL: Comparison of the effects of a controlled-release formulation of isosorbide-5-mononitrate and conventional isosorbide dinitrate on exercise performance in men with stable angina pectoris. Am J Cardiol 1990;65:1208-1212.
10. Matsui D, Hermann C, Klein J, Berkovitch M, Olivieri N, Koren G: Critical comparison of novel and existing methods of compliance assessment during a clinical trial of an oral iron chelator. J Clin Pharmacol 1994;34:944-949.
11. Rudd P, Ramesh J, Bryant-Kosling C, Guerrero D: Gaps in cardiovascular medication taking: the tip of the iceberg. J Gen Intern Med 1993;8:659-666.
12. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR: The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990;150:1881-1884.
13. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL: How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261:3273-3277.
14. Parker J: Controlled release isosorbide-5-mononitrate in angina pectoris: a comparison with standard formulation isosorbide dinitrate. Can J Cardiol 1991;7:125-130.
15. Friedman G and the ATIS Group: Comparative clinical trial of isosorbide mononitrate and isosorbide dinitrate in patients with stable angina pectoris. J Invasive Cardiol 1992;4:319-329.
16. Thadani U, Friedman R, Jones J, Heberton RK, Pierson WC: Nitrate tolerance: eccentric versus concentric twice daily therapy with isosorbide-5-mononitrate in angina pectoris (abstract). Circulation 1989;80:11-216.